Shots:
Driven by innovation and a steadfast commitment to advancing cutting-edge therapies, the biopharma industry experienced robust growth in 2024, marked by significant revenue milestones
With a projected compound annual growth rate (CAGR) of 12.87%, the global biopharma market is expected to reach $1.41 trillion by 2032. In 2024, Pfizer led the industry with total…
Shots:
Prescription drugs have an instrumental role in effectively controlling chronic diseases like heart-related conditions, diabetes, arthritis, hypertension, and cancer, among others. Unlike over-the-counter drugs, prescription drugs are advised not to be taken without the authorization of a doctor
In 2022, the global market size of prescription drugs was worth $1035.5B and is envisioned to…
Shots:
Avery spoke about the study design and the new data obtained from the P-III VOYAGER PAD trial evaluating Xarelto + Aspirin to treat peripheral artery disease presented at the 72nd ACC 2023
The data demonstrated that the treatment with the Xarelto vascular dose following LER had a 33% reduction in acute limb ischemia and a 15%…
Active Ingredient: rivaroxaban
Strength: 2.5 mg, 10 mg, 15 mg, and 20 mg
Dosage Form: Tablets
Mechanism of Action: Factor Xa inhibitors
First Approval: US (1 Jul 2011), EU (30 Sep 2008)
Revenue Analysis of Xarelto1
Xarelto has been an important driver of the revenue generated from the cardiovascular portfolio of Janssen. The blood thinner showed an increase of 4%…
Shots:
The pharmaceutical companies have shown continual efforts towards developing enhanced and innovative treatment options to address the unmet needs of patients with disease eradication being the goal of developing these treatments
Advancements in cellular and molecular biology have increased the possibilities for generating new pharmaceutical products imposing major impacts on the prevention, diagnosis, and…
Active Ingredients: Adalimumab
Strength: 40 mg/0.8 ml
Dosage Form: Syringe, Vial
Mechanism of Action: TNF-alpha inhibitors
First Approval: US (Dec 31, 2002), EU (Aug 09, 2003)
Revenue
Humira (adalimumab) has been the top-selling biologic drug product for the last few years – reaching nearly $21B in annual sales in 2021. Humira is one of the main drivers of AbbVie’s immunology…
The year 2021 witnessed the global approval of vaccines and drugs amid COVID-19. The disease has been dominating the headlines from the last two years.
No one is amazed that COVID vaccines and drugs find a place in top selling drugs this time. Pfizer & BioNTech’s Comirnaty took the first position with $36B revenue and…

